

AP Valves 2017: Case Reviews

Conduction Abnormalities: How to Avoid & Manage ?

Aug 16st, 2017

Won-Jang Kim, MD, PhD

Associate Professor, Department of Cardiology



CHA Bundang Medical Center

CHA University School of Medicine




Case

89 yo lady, DM, CKD stage 2, DOE NYHA III



CAVB

3 days later




Incidences and Impacts on Clinical Outcomes



Incidence of Left Bundle Branch Block: Varies by site, study, valve type

Post-TAVR or hospital discharge



¹Boerlage-Van Dijk K, et al., *PACE* 2014; 37: 1520-1529; ²De Carlo M, et al., *Am Heart J* 2012; 163: 492-9; ³Ferreira N, et al., *PACE* 2010; 33: 1364-1372; ⁴Fraccaro C, et al., *Am J Cardiol* 2011; 107: 747-754; ⁵Guetta V, et al., *Am J Cardiol* 2011; 108: 1600-1605; ⁶Munoz-Garcia A, et al., *Rev Esp Cardiol* 2010; 63(12): 1444-51; ⁷Piazza N, et al., *EuroIntervention* 2010; 6(4): 475-84; ⁸Saia F, et al., *Catheter Cardiovasc Interv* 2012; 79(5): 7712-9; ⁹Jilalhawi H, et al., *Am Heart J* 2009; 157: 860-6; ¹⁰Calvi V, et al., *J Interv Card Electrophysiol* 2012; 34: 189-95; ¹¹Pereira E, et al., *PACE* 2013; 36(5): 559-69; ¹²Petronio AS, et al., presented at EuroPCR 2014; ¹³Testa L, et al., *Circulation* 2013; 127: 1300-1307; ¹⁴Eksik A, et al., *J Invasive Cardiol* 2013; 25(6): 305-309; ¹⁵Nazif T, et al., *Eu r Heart J* 2013; epub ahead of print; ¹⁶Urena M, et al., *J Am Coll Cardiol Intv* 2014; 7(2): 128-36; ¹⁷Urena M, et al., *J Am Coll Cardiol* 2012; 60(18): 1743-52; ¹⁸Gutierrez M, et al., *Am Heart J* 2009; 158: 302-8.

Impact of New LBBB on Mortality

Inconclusive data may result from how pacemakers are treated in the analysis

Study	Valve Type, N	% LBBB Discharge	% LBBB 1 Year	Impact on 1-Yr All-Cause Mortality	Patients in Analysis	Post-TAVI PPM which were excluded
De Carlo ¹	MCV N=275	26.9%	NR	No (p=0.37)	All new LBBB before discharge	PPM prior to discharge
Pereira ²	MCV N=65	37.5%*	NR	No (p=0.111)	New post procedural LBBB	PPM prior to discharge
Houthuizen ³	MCV N=387 EDW N=292	34.3%	NR	Yes (p=0.006)	New LBBB within 7 days	All post-TAVI PPM
Houthuizen ⁴	MCV N=223 EDW N=253	28.7%	22.7%	Yes (p=NR)	New LBBB that persisted at 1 year	All post-TAVI PPM
Urena ⁵	EDW N=202	13.2%	5.0%	No (p=0.610)	New LBBB at discharge	PPM prior to discharge
Franzoni ⁶	MCV N=87 EDW N=151	17.2%	NR	No (p=0.42)	New LBBB at discharge	NR
Testa ⁷	MCV N=818	27.4%	NR	No (p=0.3)	New LBBB at discharge	PPM within 48 hrs of TAVI
Nazif ⁸	EDW N=1151	10.5%	8.5%	No (p=0.73)	New LBBB at discharge	PPM prior to discharge
Urena ⁹	EDW N=668	11.8%	NR	No (p=0.174)	New LBBB at discharge	NR
Wenaweser ¹⁰	MCV N=1015	NR	23.1%	No (p=0.393)	New LBBB at 30 days	All post-TAVI PPM

¹De Carlo M, et al., *Am Heart J* 2012; 163: 492-9; ²Pereira E, et al., *PACE* 2013; 36(5): 559-69; ³Houthuizen P, et al., *Circulation* 2012; 126: 720-728; ⁴Houthuizen P, et al., *EuroIntervention* 2014; 9(10): 1142-1150; ⁵Urena M, et al., *J Am Coll Cardiol* 2012; 60(18): 1743-52; ⁶Franzoni I, et al., *Am J Cardiol* 2013; 112(4): 554-559; ⁷Testa L, et al., *Circulation* 2013; 127: 1300-1307; ⁸Nazif T, et al., *Eur Heart J* 2013; epub ahead of print; ⁹Urena M, et al., *J Am Coll Cardiol Interv* 2014; 7(2): 128-36; ¹⁰Wenaweser P, et al., presented at EuroPCR 2013




Incidence of Pacemaker post TAVR

	Studies	Patients	Pacemaker	Sapien	CoreValve
Khatri et al	44	12,116	13.1%	6.4%	25.4%
Siontis et al	41	11,210	17%	6%	28%

- Meta-analyses have analyzed the rates of new PPM with the early generation devices
 - Medtronic CoreValve ~ 25-32%
 - Edwards Sapien (XT) ~ 6%


Khatri. Ann Intern Med 2013, Siontis. JACC 2014, Mohananey. Cir Cardiovasc Intv 2017

Newer Generation Devices: Edwards SAPIEN 3




Nazif TM. *J Am Coll Cardiol Interv* 2015;8:60-9.; Webb JG. *J Am Coll Cardiol Interv* 2015;8:1797-806.; Leon MB. *N Engl J Med* 2016;374:1609-20.; Kodali S. *Eur Heart J*. 2016;37:2252-62

Newer Generation Devices: Medtronic Evolut-R



Linke A. *Eur Heart J* 2014;35:2672-84; Popma J. *J Am Coll Cardiol* 2014;63:1972-81; Adams D. *N Engl J Med* 2014;370:1790-8; Manoharan G. *J Am Coll Cardiol Interv* 2015;8:1359-67; Williams MR presented at ACC 2016, Forrest J presented at ACC 2017

Clinical Impact of PPM After TAVR






PPM implantation is not associated with increased risk of death, CV death, stroke, MI both at short- and long-term follow-up.

Mechanism and Time Course of Recovery



Anatomical Considerations


- Close proximity of the aortic valve to the cardiac conduction system¹
- Distance between non-coronary cusp and His-bundle: on average, 6.3 mm
- Distance varies among individuals, but is usually <10 mm



Anatomical Considerations


Prosthetic valves may contact the conduction system, causing injury (inflammation, or in this case, hemorrhage)¹

Appropriately
implanted
Edwards
Sapien valve:



Following removal of
prosthetic valve,
hemorrhagic lesions
observed

Hematoxylin
and eosin, x10



Hematoxylin
and eosin, x40

endocardium
hemorrhagic band
His bundle
myocardial fiber
hemorrhage
Conduction
tissue fibers
myocardial fibers

¹ Moreno R., et al., *Circulation* 2009; 120: e29-30.

Mechanism of Conduction Disturbances

- *Conduction abnormalities may resolve due to the transient nature of some TAVR-induced tissue injury*

Mechanical (Direct) Injury


- Wall tension due to radial force
- Procedural Inflammation
- Procedural Edema

Ischemic (Indirect) Injury

- Tissue compression during BAV
- Hypotension during rapid pacing (BAV procedure)
- Other hypotensive episodes

Conduction Disturbances Resolve with Time

- Paired analyses in ADVANCE II showed that 42% of new LBBB and 65% of new 1st degree AV block resolved spontaneously by day 30¹



■ New-onset LBBB ■ New-onset 1st degree AV block

Patients with normal baseline AV conduction were considered for new-onset AV block. Patients with normal baseline IV conduction were considered for new-onset LBBB.

New-onset is defined as a new conduction disturbance which initiates within 48 hours of TAVI.


Patients receiving new permanent pacemakers were excluded.

Paired data for each type of conduction disturbance: LBBB n=114, 1st degree n=74

¹Petronio S, et al., presented at EuroPCR 2014

Timing of Permanent Pacemaker Implants

- Of pacemakers implanted within 10 days of TAVI, the majority had been implanted by day 3 in both PARTNER and ADVANCE.
- Some proportion of conduction disturbances (all types) will spontaneously resolve, though the time course for a given patient is difficult to predict.
- Consider watchful waiting.



Predictors : Manageable or not



Predictors of Conduction Disturbances

- More than 40 studies have been published on predictors of post-TAVR conduction disturbances (CDs) and permanent pacemaker implant (PPM)
- Studies varied in size, rigor, and the univariable characteristics which were considered, but some central themes emerged:


Clinical	Anatomical	Procedure and Operator-Related
<ul style="list-style-type: none">• Male gender³• Age > 75 years⁹• Previous MI³• RBBB^{2,3,4,5,7}• Other pre-existing conduction disturbances^{3,4,8,9}	<ul style="list-style-type: none">• Variations in location of LBBB exit point¹• Septum thickness^{1,6}• Thickness of the non-coronary cusp¹• Membranous septum length¹²	<ul style="list-style-type: none">• Radial force of the prosthesis³• Implant Depth^{2,3,7}• Balloon Aortic Valvuloplasty⁸• Application of PPI guidelines¹⁰• Learning Curve¹¹

¹Jilaihawi, et al. Am Heart J 2009; ²Munoz-Garcia, et al. JACC CV 2012; ³Piazza et. al. EuroIntervention 2010; ⁴De Carlo, et. al. Am Heart J 2012; ⁵Calvi, et. al. JICE 2011; ⁶Saia, et. al. Cath Card Interv 2012; ⁷Fracarao, et. al. Am J Card 2011; ⁸Khawaja, et. al. Circ 2011; ⁹Schroeter et. al. EuroPACE 2011; ¹⁰Wenaweser, et. al. presented at EuroPCR 2013; ¹¹Meredith, et. al. presented at TCT 2012; ¹²Hamdan, et al. JACC Cardiovasc Interv 2015


Procedural Considerations – Manageable !

ADVANCE II confirmed that implant depth is the strongest procedural predictor of new PPM¹


Implant Depth



Oversizing



Post-Dilatation



Error bars are standard error

Implant depth defined as the distance from the lower edge of the non-coronary leaflet to the ventricular edge of the frame

*Oversizing occurs when a valve is implanted in an annulus that is smaller than the range defined by the CoreValve sizing guide

% Oversizing = $100 \times \left(\frac{\text{Perimeter of CoreValve} - \text{CT Derived Perimeter of the Annulus}}{\text{CT Derived Perimeter of the Annulus}} \right)$

¹Petronio S, et al., presented at EuroPCR 2014






How to Avoid?

1. High, Shallow Implantation



Depth of Implantation: CoreValve




Depth of Implantation: CoreValve

- Kammler et al: MDCT in 53 Patients before and after TAVR with CoreValve
- Depth of Implantation:
 - PPM (9.7 vs 6.3 mm, $p=0.001$)
 - >6 mm depth sensitivity 89%



Device Depth : CoreValve



6 AP centers, N=117 patients



29 mm with PPM

NCC, non-coronary cuspid; LCC, left coronary cusp; PPM, permanent pacemaker


Device depth vs. PPM



Sensitivity 60.87%, Specificity 74.47%
PPV 35.14%, NPV 87.5%
Accuracy 70.94%




Why do we perceive a relative difference?



LAO 18 CRA 4
2-chamber view


Traditional – LVOT foreshortend



RAO 40 CAU 38
3-chamber view


LVOT elongated

Intersection between aortic annulus and delivery catheter S-curves




Delivery catheter

Aortic annulus



Depth of Implantation SAPIEN

- Binder: MDCT in 89 Patients before and after TAVR with ESV
- Depth of Implantation:
 - LBBB/CHB (5.5 vs 3.4mm, $p=0.01$)
 - PPM (7.1 vs 3.5mm, $p=0.001$)



Binder et al. JACC Cardiovasc Interv 2013;6:462-8.


How to Avoid ?

2. Not too much over-size or stretch





THV Over-Sizing

- Katsanos et al: MDCT in 94 Patients before and after TAVR with SAPIEN
- Independent predictors of PPM included
 - Depth of Implantation: OR 1.4 per mm
 - Annulus Area oversizing > 15%: OR 5.3



Stretching Index vs. PPM



Sensitivity 86.96%, Specificity 94.68%
PPV 80%, NPV 96.74%
Accuracy 93.2%

Perimeter Stretching Index by CT Examples – No PPM

31 mm device



Perimeter 91mm; Area 592 mm²


CoreValve, 31 mm
Calculated Perimeter 97.3 mm

Measured Perimeter 91 mm

= 1.07

Perimeter Stretching Index by CT Examples – PPM

29 mm device



CoreValve: 29mm
Calculated Perimeter 91.1 mm

Measured Perimeter 73.5 mm

= 1.24


Perimeter 73.5mm; Area 404 mm²

Beyond Technical Issues





Clinical Impact of Conduction Disturbances: New LBBB and Recovery of LVEF


1151 Patients from PARTNER



Clinical Impact of LBBB after TAVR



Impact of PPM on Duration of Hospitalization and Re-Hospitalization



- PARTNER : 1973 Sapien
- Post-procedure hospitalization:
PPM vs No-PPM: 7.3 vs 6.2 days, $p < 0.001$

Additional Costs of PPM after TAVR

Table 5 Factors associated with hospital stay cost (valve excluded): results of the multivariable analysis.

Variable	Model: STS ^a		Model: LES ^b	
	Rate ratio (95% CI)	P	Rate ratio (95% CI)	P
STS score at inclusion > 10%	1.15 (1.05–1.27)	< 0.01	NA	NA
LES at inclusion > 20%	NA	NA	NR	NR
Warfarin use at inclusion	1.15 (1.04–1.28)	0.01	1.16 (1.05–1.29)	< 0.01
Transapical approach	1.14 (1.03–1.27)	0.02	1.14 (1.02–1.27)	0.02
Use of hybrid room	NR	NR	1.17 (1.02–1.36)	0.03
Complication(s) during procedure	1.19 (1.06–1.33)	< 0.01	1.17 (1.05–1.29)	< 0.01
Pacemaker implantation during hospitalization	1.36 (1.20–1.54)	< 0.001	1.36 (1.21–1.54)	< 0.001
Adjusted R ²	0.14	0.13		

CI: confidence interval; LES: Logistic Euroscore; NA: not applicable; NR: not retained in the final model because not significant; STS: Society of Thoracic Surgeons.

^a STS score and all other variables except those used for LES.


^b LES and all other variables except those used for STS.

Estimates of the additional cost of complications with respect to different cost units and categories.

Variables	Number of events	Cost unit (in €)				Cost category (in €)			Total in-hospital costs (in €)
		Normal ward (in €)	ICU (in €)	Cath lab/OR (in €)	Other costs (in €)	Staff costs (in €)	Material costs (in €)	Infrastructure costs (in €)	
Constant (predicted costs in case of no complication)		3707**	3960**	23,815**	2666**	7319**	23,024**	3403**	34,351**
TA instead of TF-TAVI	66	2495**	-393	-104	576	1836 ⁺	-968	1422**	2307
Access site bleeding – life threatening	18	-1822 ⁺	4277	1142	1804 ⁺	1938	3709 ⁺	-80	5556
Access site bleeding – major	13	17	590	1589	-234	-59	2674	-545	2066
Access site bleeding – minor	8	491	840	-74	698	1269	265	455	1989
Non-access site bleeding – life threatening	4	929	37,322 ⁺	1146	8553 ⁺	24,031 ⁺	14,238 ⁺	9217**	47,494 ⁺
Non-access site bleeding – major	7	758	-1392	-197	163	-846	113	197	-533
Non-access site bleeding – minor	12	654	-774	476	11	264	-169	335	432
Vascular complication – major	19	814	455	-611	-55	789	-1493	910	210
Vascular complication – minor	26	780	180	364	286	710	558	295	1563
Stroke (including TIA)	8	1573	-3350	3168	-141	-378	1423	187	1227
Acute kidney injury – stage 1	14	1242	-1688	-185	-602	-519	-438	-238	-1203
Acute kidney injury – stage 2	10	1535	9530 ⁺	-545	1181	6034 ⁺	3721	2050 ⁺	11,811 ⁺
Acute kidney injury – stage 3	12	362	17,040**	-1358	4043**	11,931**	4356 ⁺	4192**	20,468**
Second valve	4	-994	-1174	13,856**	371	-924	18,302**	-611	16,767**
Atrial flutter/fibrillation	12	122	1028	1001	245	621	496	226	1292
Pacemaker implantation	56	380	-715	1946 ⁺	370	849	-95	690 ⁺	1441
Other severe cardiac dysrhythmia	11	1586	5490 ⁺	200	3224 ⁺	5592	3001 ⁺	2028	10,611 ⁺
Moderate aortic insufficiency	11	-363	510	596	-592	-81	130	-1	46
Adjusted R ²		0.06	0.58	0.28	0.45	0.54	0.45	0.49	0.51
N		163	163	163	163	163	163	163	163


In addition to the complications shown above, 'other complications' as described in Table 1 were also included in the regression analyses.

Indication for PPM After TAVR



N=152, 98% MCV

Steinberg. Am Heart J. 2012;164:664-71




N=173 ESV

Nazif. JACC Intervention 2015

Rupture/ PPM vs. PVL

Annulus Size Assessment is Crucial: Multidisciplinary Image





Conclusions

- Conduction disturbances and PPM are frequent complication of TAVR
- Most of them resolve over time as the tissue heals and adapts to the THV valve
- However, the conduction disturbances that remain may not be benign
 - LBBB deterioration to more severe conduction disturbances with time
 - Asynchronous contraction patterns due to LBBB or RV pacing may lead to heart failure
- Risk is determined by a complex between patient substrate (RBBB, calcification, etc) and procedural factors
- Careful attention to positioning THV valves 4-6 mm or less relative to the annulus (self-expanding) and less-oversizing (balloon-expandable) will minimize conduction disturbances
- Watchful waiting prior to PPM implantation may be warranted (conservative strategy by guideline)


Thank you.




Aortic Annulus on MSCT



Oblique Coronal Image









Oblique Sagittal Image




Transverse Image

Aortic Annulus on MSCT




Aortic Annulus on MSCT


Coronal measurements do not equal those from the annular plane



Coronal Image




Aortic Annulus




Oblique Coronal Image

Aortic Annulus on MSCT


Sagittal measurements do not equal those from the annular plane



Sagittal Image




Oblique Sagittal Image



Aortic Annulus

The Aortic Annulus on MSCT



New CT Parameters



Area-derived virtual Diameter


$$\sqrt{(4 \cdot \text{Area} / \pi)}$$



Area

Minimum Diameter

Ellipticity Ratio
Maximum Diameter/
Minimum Diameter



Maximum Diameter


Perimeter



Perimeter-derived virtual Diameter

$$\text{Perimeter} / \pi$$

CT Sizing for Edwards Valve



J Am Coll Cardiol Img. 2013;6(2):249-262.



CT Sizing for Edwards S3

3D Area - derived Diameter (mm)	20.0	20.2	20.5	20.7	21.0	21.1	21.4	21.7	22.0	22.3	22.6	22.8	23.0	23.1	23.4	23.7	23.9	24.0	24.2	24.7	
3D Annular Area (mm ²)	314	320	330	338	346	350	360	370	380	390	400	410	415	420	430	440	450	452	460	480	
% Annular Area Over (+) or Under (-) Nominal by 3D CT	23mm	29.3	28.9	23.0	20.1	17.3	16.0	12.8	9.7	6.8	4.0	1.5	-1.0	-2.2	-3.3	-5.6	-7.7	-9.8			
	26mm											29.8	28.6	25.1	23.6	20.7	18.0	15.3	14.8	12.8	8.1
	29mm																				

25.0	25.2	25.5	25.7	26.0	26.2	26.4	26.5	26.7	26.9	27.2	27.4	27.6	27.9	28.0	28.1	28.3	28.5	28.8	29.0	29.2	29.4	29.5	29.6	29.9	30.1	30.3
490	500	510	520	530	540	546	550	560	570	580	590	600	610	615	620	630	640	650	660	670	680	683	690	700	710	720
5.9	3.8	1.8	-0.2	-2.1	-3.9	-4.9	-5.6	-7.3	-8.9																	
	29.8	27.3	24.8	22.5	20.2	18.9	18.0	15.9	13.9	11.9	10.0	8.2	6.4	5.5	4.7	3.0	1.4	-0.2	-1.7	-3.1	-4.6	-5.0	-5.9	-7.3	-8.6	-9.9




CT Sizing for CoreValve

Valve Size	Aortic Annulus Measurements			Sinus of Valsalva Diameter	Native Leaflet to Sinotubular Junction Length	Ascending Aorta Diameter*
	Diameter	Perimeter	Area Range			
23	18-20 mm	56.5-62.8 mm	254.5-314.2 mm	≥ 25 mm	≥ 15 mm	≤ 34 mm
26	20-23 mm	62.8-72.3 mm	314.2-415.5 mm	≥ 27 mm	≥ 15 mm	≤ 40 mm
29	23-26 mm	72.3-81.7 mm	415.5-530.9 mm	≥ 29 mm	≥ 15 mm	≤ 43 mm
31	26-29 mm	81.7-91.1 mm	530.9-660.5 mm	≥ 29 mm	≥ 15 mm	≤ 43 mm


*Ascending Aorta measurements are taken at 30 mm from the aortic annulus for the 23 mm device and at 40 mm from the aortic annulus for the 26, 29, and 31 mm devices.



Valve position too high?




LAO 18 CRA 4



Concomitant TEE

Valve position correct?



RAO 40 CAU 38

